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BACKGROUND: The CXCL12/CXCR4 chemokine ligand/receptor axis controls 
(progenitor) cell homeostasis and trafficking. So far, an atheroprotective role of 
CXCL12/CXCR4 has only been implied through pharmacological intervention, 
in particular, because the somatic deletion of the CXCR4 gene in mice is 
embryonically lethal. Moreover, cell-specific effects of CXCR4 in the arterial wall 
and underlying mechanisms remain elusive, prompting us to investigate the 
relevance of CXCR4 in vascular cell types for atheroprotection.
METHODS: We examined the role of vascular CXCR4 in atherosclerosis and 
plaque composition by inducing an endothelial cell (BmxCreERT2-driven)–specific 
or smooth muscle cell (SMC, SmmhcCreERT2- or TaglnCre-driven)–specific 
deficiency of CXCR4 in an apolipoprotein E–deficient mouse model. To 
identify underlying mechanisms for effects of CXCR4, we studied endothelial 
permeability, intravital leukocyte adhesion, involvement of the Akt/WNT/β-
catenin signaling pathway and relevant phosphatases in VE-cadherin expression 
and function, vascular tone in aortic rings, cholesterol efflux from macrophages, 
and expression of SMC phenotypic markers. Finally, we analyzed associations 
of common genetic variants at the CXCR4 locus with the risk for coronary 
heart disease, along with CXCR4 transcript expression in human atherosclerotic 
plaques.
RESULTS: The cell-specific deletion of CXCR4 in arterial endothelial cells (n=12–
15) or SMCs (n=13–24) markedly increased atherosclerotic lesion formation in 
hyperlipidemic mice. Endothelial barrier function was promoted by CXCL12/
CXCR4, which triggered Akt/WNT/β-catenin signaling to drive VE-cadherin 
expression and stabilized junctional VE-cadherin complexes through associated 
phosphatases. Conversely, endothelial CXCR4 deficiency caused arterial leakage 
and inflammatory leukocyte recruitment during atherogenesis. In arterial 
SMCs, CXCR4 sustained normal vascular reactivity and contractile responses, 
whereas CXCR4 deficiency favored a synthetic phenotype, the occurrence 
of macrophage-like SMCs in the lesions, and impaired cholesterol efflux. 
Regression analyses in humans (n=259 796) identified the C-allele at rs2322864 
within the CXCR4 locus to be associated with increased risk for coronary heart 
disease. In line, C/C risk genotype carriers showed reduced CXCR4 expression 
in carotid artery plaques (n=188), which was furthermore associated with 
symptomatic disease.
CONCLUSIONS: Our data clearly establish that vascular CXCR4 limits 
atherosclerosis by maintaining arterial integrity, preserving endothelial barrier 
function, and a normal contractile SMC phenotype. Enhancing these beneficial 
functions of arterial CXCR4 by selective modulators might open novel therapeutic 
options in atherosclerosis.
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The chemokine receptor CXCR4 and its cognate li-gand CXCL12 are best known for their role in the homing of progenitor cells to the bone marrow 
and their mobilization to the periphery.1 Moreover, the 
importance of CXCR4 and CXCL12 in cell homeostasis, 
organ development, and vascularization explains why 
targeted disruption of either gene results in embryonic 
or perinatal lethality.2–4 Stress-induced progenitor cell 
mobilization has been linked to a double-edged role of 
the CXCL12/CXCR4 axis after arterial injury. Whereas 
recruitment of angiogenic early outgrowth cells medi-
ated by CXCL12/CXCR4 contributes to vascular regen-
eration, the mobilization of smooth muscle progenitor 
cells drives injury-induced neointima formation.1,5 How-
ever, CXCR4 is not only expressed on progenitor cells, 
but also on endothelial cells (ECs), vascular smooth 
muscle cells (SMCs), and diverse leukocyte subsets, 
all of which play a role in neointima formation and in 
native or diet-induced atherosclerosis.1,6 For instance, 
a protective role of endothelial CXCR4 promoting re-
endothelialization after endothelial denudation has 
been revealed during neointima formation.7 In turn, an 
atheroprotective role of the CXCL12/CXCR4 axis has 
been related to the control of neutrophil numbers and 
activation,8,9 and microparticle-mediated recruitment of 
angiogenic cells, as well.10
Given that somatic deletion of the CXCR4 gene in 
mice is embryonically lethal, the atheroprotective role 
of CXCR4 has so far been implied by relying on bone 
marrow chimeras or using pharmacological inhibitors, 
eg, systemic treatment with a CXCR4 antagonist.8 Be-
yond that, vascular cell–specific effects of CXCR4 in the 
arterial wall and underlying mechanisms have not been 
elucidated in the context of atherosclerosis. Likewise, 
genome-wide association studies have validated signifi-
cant associations between single nucleotide polymor-
phisms near CXCL12 as a lead gene in the 10q11 locus 
and the risk of coronary artery disease and early myo-
cardial infarction,11,12 whereas a role of CXCR4 variants, 
in particular, those associated with cardiovascular risk 
beyond lipid levels,13 remains unknown.
Here, we examined the role of vascular CXCR4 in 
atherosclerosis by introducing an EC-specific and SMC-
specific deficiency of Cxcr4 in a mouse model of diet-
induced atherosclerosis, identified mechanisms under-
lying atherosclerosis-related effects of CXCR4 in these 
cell types, and analyzed the association of common 
CXCR4 variants with the risk for coronary heart disease 
(CHD), and CXCR4 expression in human atherosclerosis, 
as well.
METHODS
Please see the online-only Data Supplement for expanded 
methods.
Animals
All mice were on a C57/Bl6 background (online-only Data 
Supplement Table I). For atherosclerosis studies, mice were 
fed a high-fat diet (HFD) containing 21% fat and 0.15% to 
0.2% cholesterol (Altromin 132010, Sniff TD88137) for 12 
weeks. All animal studies were approved by the local ethical 
committee.
Lesion Analysis and Intravital  
Microscopy
For analysis of atherosclerotic lesions, the aortic root and tho-
racoabdominal aorta were stained for lipid depositions with 
Oil Red O. Lesions in the root were quantified and averaged 
in 3 to 5 sections per mouse. Immunohistochemistry was 
performed to assess cellular composition. Leukocyte adhe-




• We show for the first time that the chemokine recep-
tor CXCR4 in vascular cells limits atherosclerosis.
• Mechanistically, the CXCL12/CXCR4 chemokine 
ligand/receptor axis promotes endothelial barrier 
function through VE-cadherin expression and the 
stabilization of junctional VE-cadherin complexes.
• In arterial smooth muscle cells, CXCR4 sustains vas-
cular reactivity responses and a contractile smooth 
muscle cell phenotype, whereas CXCR4 deficiency 
favors the occurrence of macrophage-like smooth 
muscle cells in atherosclerotic plaques and impairs 
cholesterol efflux.
• In humans, we identified a common allele vari-
ant within the CXCR4 locus to be associated with 
reduced CXCR4 expression in carotid artery plaques 
and increased risk for coronary heart disease.
What Are the Clinical Implications?
• Our data reveal that specifically enhancing the 
atheroprotective functions of arterial CXCR4 by 
selective modulators may open novel therapeutic 
options in atherosclerosis.
• Because systemic approaches to boost CXCR4 
function carry a substantial risk of side effects and 
suboptimal efficacy, eg, due to proatherogenic 
effects of CXCR4-bearing hematopoietic cells, 
we envision a regional application of selectively 
targeted CXCR4 agonists or modulators through 
peri- or intravascular routes as a novel therapeutic 
option in atherosclerosis.
• Regional boosting of vascular CXCR4 may be 
accomplished using polymer- or nanoparticle-
based delivery, as exemplified for microR-126-3p, 
which we previously showed to de-repress CXCR4 
activity in endothelial cells.
Döring et al
July 25, 2017 Circulation. 2017;136:388–403. DOI: 10.1161/CIRCULATIONAHA.117.027646390
In Vivo Permeability Assay
Endothelial permeability in the aortic arch was studied using 
Evans blue (1%, 30 minutes).
Cell Culture
Human aortic endothelial cells (hAoECs, Lonza), SV-40–
transformed mouse endothelial cells, and human aortic vas-
cular smooth muscle cells (hAoSMCs, Lonza) were used.
Small Interfering RNA Silencing and Gene 
Expression Analysis
Specific knock-down of β-catenin and CXCR4 (online-only 
Data Supplement Table II) in hAoECs was accomplished by 
application of RNA interference technology (Qiagen). RNA 
was isolated using RNeasy kits and Tissuelyser (both Qiagen) 
and reverse transcribed using Moloney murine leukemia virus 
reverse transcriptase (Promega). Quantitative real-time poly-
merase chain reaction was performed using the Sybrgreen 
(online-only Data Supplement Table III). Gene expression was 
normalized to GAPDH using the ΔΔCt method.
Transcription-Based Reporter Assay
WNT/β-catenin signaling activity was quantified in hAoECs 
by using a β-catenin–activated reporter system containing 
multimerized transcription factor/lymphoid enhancer-binding 
factor DNA-binding sites with inserted Gaussia luciferase as 
a reporter gene. Conditioned media were analyzed using the 
Gaussia luciferase assay kit (New England Biolabs) and a plate 
luminometer (Tecan).
In Vitro Permeability and Scratch Assay
An in vitro permeability assay (Millipore) was performed with 
hAoEC monolayers grown in 96-well cell culture inserts with 
a semipermeable membrane using fluorescein isothiocya-
nate-dextran. A scratch was introduced by dragging a sterile 
pipette tip across confluent hAoSMC monolayers to create a 
cell-free path, which was used for monitoring cell migration.
Vascular Reactivity
The thoracic aorta was divided into equal rings. Each aortic 
ring was connected to a force transducer in organ chambers 
using a passive tension of 2g for subsequent manipulation.
Analysis of CXCR4 in Humans
We examined the association of 345 common variants at the 
CXCR4 locus (±25 kB) in association with CHD by using data 
on altogether 92 516 CHD cases and 167 280 controls (see 
online-only Data Supplement Table IV for details of data sets 
included). Human carotid artery endarterectomy specimens 
(n=218) were collected in a cohort of patients undergoing 
vascular surgery, and utilization of human vascular tissues 
was approved by the Ethics Committee of the Medical Faculty 
at the TU Dresden (EK316122008). Quantification of CXCR4 
mRNA expression and genotyping of rs2322864 in human 
specimens was performed and correlated with the clinical 
phenotype.
Statistical Analysis
All data are expressed as mean±SD or mean±standard error 
of the mean, as indicated. Statistical analyses were performed 
using GraphPad Prism 6 (GraphPad Software Inc). After test-
ing for normality, unpaired Student t test (with Welch cor-
rection for mouse studies), Mann-Whitney, 1-way analysis 
of variance (ANOVA) with the Tukey or Sidak multiple com-
parisons test, Kruskal-Wallis test with Dunn post test, 2-way 
ANOVA or 2-way repeated-measures ANOVA with Bonferroni 
post test were used, as appropriate. P values <0.05 were con-
sidered statistically significant.
RESULTS
CXCR4 on Arterial ECs Is Atheroprotective
To focus on EC-specific effects of CXCR4 in atheroscle-
rosis-prone mice lacking the Apoe gene (Apoe–/–) and 
subjected to hyperlipidemia, Cxcr4-floxed (Cxcr4fl/fl) 
Apoe–/– mice were crossed with BmxCreERT2-expressing 
mice (termed BmxCre), mediating efficient tamoxifen-
inducible Cxcr4 deletion in arterial ECs (Figure  1A, 
online-only Data Supplement Figure IA).7 After 12 
weeks of HFD, BmxCre+Cxcr4fl/flApoe–/– mice displayed 
larger atherosclerotic lesions in the aortic root (Fig-
ure 1B through 1D), the aortic arch (Figure 1E), and the 
aorta (Figure 1F), in comparison with BmxCre–Cxcr4fl/
flApoe–/– controls. Whereas the relative SMC content 
(Figure  1G) and collagen content (online-only Data 
Supplement Figure IB) in aortic root lesions were unal-
tered, macrophage content (Figure 1H and 1I, online-
only Data Supplement Figure IC) and the necrotic core 
area (Figure 1J, online-only Data Supplement Figure ID) 
were increased in BmxCre+Cxcr4fl/flApoe–/– mice. Con-
versely, the relative presence of ECs in root lesions was 
decreased in BmxCre+ Cxcr4fl/flApoe–/– mice (online-only 
Data Supplement Figure IE and IF). Whereas the den-
sity of ECs lining the plaque cap was changed (online-
only Data Supplement Figure IG), the number of in-
tercellular adhesion molecule-1–positive cells lining the 
plaque cap, likely corresponding to activated ECs, was 
increased (Figure 1K and 1L). This correlated with an 
increased adhesion of inflammatory monocytes and 
neutrophils to the carotid artery of tumor necrosis 
factor α–treated BmxCre+Cxcr4fl/flApoe–/– mice on HFD 
(Figure 1M and 1N).
The serum levels of CXCL12 (online-only Data 
Supplement Figure IH), cholesterol, and triglycerides, 
or body weight did not significantly differ between 
BmxCre– and BmxCre+Cxcr4fl/flApoe–/– mice after HFD 
(online-only Data Supplement Table V), nor were 
numbers of leukocytes, neutrophils, monocytes, lym-
phocytes, and platelets altered in peripheral blood 
(online-only Data Supplement Figure II, online-only 
Data Supplement Table V). In the context of arterial 
injury, EC-specific Cxcr4 deficiency was found to de-
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crease mobilization of Sca1+CD31+Flk1+ and Lin–Sca1+ 
progenitor cells,7 often referred to as circulating an-
giogenic early-outgrowth cells and SMC progeni-
tors,5,14 respectively. Because both progenitor subsets 
have been associated with atheroprotection,15,16 their 
mobilization was examined by flow cytometry. No dif-
ferences in these subpopulations or their CXCR4 ex-
pression were observed between BmxCre– and Bmx-
Cre+ Cxcr4fl/flApoe–/– mice after HFD (online-only Data 
Supplement Figure IJ through IQ). This indicates that 
Bmx is not expressed in these subsets and thus mainly 
affects resident arterial ECs. Taken together, our data 
reveal a proatherogenic effect of endothelial Cxcr4 
deletion, associated with an inflammatory phenotype 
of the endothelium and increased macrophage content 
in the atherosclerotic lesions.
CXCR4 on Arterial SMCs Is 
Atheroprotective
We next examined the contribution of CXCR4 in resi-
dent SMCs to atherosclerosis, crossing Cxcr4fl/flApoe–/– 
mice with TaglnCre-expressing mice for constitutive 
Cxcr4 deletion in SMCs17 (Figure 2A, online-only Data 
Supplement Figure IIA). In comparison with TaglnCre–
Cxcr4fl/flApoe–/– controls, the lesion size in the aortic 
root (Figure 2B and 2C) and in the aorta (Figure 2D) 
was significantly increased in TaglnCre+ Cxcr4fl/flApoe–/– 
Figure 1. CXCR4 on arterial endothelial cells is atheroprotective.  
Cxcr4fl/flApoe–/– mice were crossed with BmxCreERT2-expressing mice (termed BmxCre), to allow for tamoxifen-inducible 
Cxcr4 deletion in arterial endothelial cells. BmxCre+Cxcr4fl/flApoe–/– mice versus BmxCre–Cxcr4fl/flApoe–/– controls were ana-
lyzed after 12 weeks of high-fat diet (HFD), unless otherwise indicated. A and B, Experimental scheme. C through F, Lesion 
area measured after Oil Red O or HE staining in the aortic root (C, D; n=12–14), aortic arch (E; n=12–15), and aorta (F; 
n=12–15). Representative images are shown for aortic root (C). Scale bars=500 µm. G, SMC content in aortic root lesions, 
as quantified after staining for SMA (n=12–14). H and I, Macrophage content in aortic root lesions, as quantified after 
staining for Mac2 (n=12–14). Representative images are shown in H. J, Necrotic core area in aortic root lesions, as quanti-
fied by anucleated area measurement (n=12–14). K and L, The number of ICAM-1+ cells per micrometer plaque lining in 
aortic root lesions (n=10–13). Representative images are shown in K. M and N, Representative images (M) and quantifica-
tion (N) of intravital microscopy of leukocyte adhesion to TNFα-stimulated carotid arteries of BmxCre+Cxcr4fl/flApoe–/– versus 
BmxCre–Cxcr4fl/flApoe–/– mice after 8 weeks of HFD. Leukocyte labeling was performed for CD11b (all myeloid cells), Ly6G 
(neutrophils), or Ly6C (monocytes) (n=7–10). D through N, Data represent mean±SD. *P<0.05. **P<0.01. ***P<0.001, as 
analyzed by the Student t test with Welch correction or Mann-Whitney test, as appropriate. HE indicates hematoxylin and 
eosin; ICAM-1, intercellular adhesion molecule-1; SMA, smooth muscle actin; SMC, smooth muscle cell; Tamox., tamoxifen; 
and TNFα, tumor necrosis factor α. 
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mice after 12 weeks of HFD. No differences in plaque 
size of the aortic arch (Figure 2E) or in lesional mac-
rophage content or necrotic core area of aortic root 
lesions (Figure  2F and 2G, online-only Data Supple-
ment Figure IIB and IIC) were observed. In contrast, 
the relative SMC content of aortic root lesions was sig-
nificantly decreased in TaglnCre+Cxcr4fl/flApoe–/– versus 
TaglnCre–Cxcr4fl/flApoe–/– mice (Figure  2H). However, 
absolute SMC numbers collagen content and the per-
centage of TUNEL+ (terminal deoxynucleotidyl transfer-
ase dUTP nick end labeling) cells, indicative of apop-
tosis, were unaltered (online-only Data Supplement 
Figure IID through IIF). Whereas leukocyte, neutrophil, 
monocyte, lymphocyte, and platelet counts in periph-
eral blood, and CXCL12 serum levels were similar in 
TaglnCre– and TaglCre+ Cxcr4fl/flApoe–/– mice (online-
only Data Supplement Figure IIG and IIH, online-only 
Data Supplement Table VI), cholesterol and triglyceride 
serum levels were lower and body weight was slightly 
decreased in TaglnCre+Cxcr4fl/flApoe–/– mice (online-only 
Data Supplement Table VI).
As an alternative to constitutive SMC-specific Cxcr4  
deletion, we studied atherosclerosis in SmmhcCre+ 
Cxcr4fl/flApoe–/– mice (Figure  2I), enabling a tamoxi-
fen-inducible Cxcr4 deletion in SMCs.18 Whereas le-
sion size did not differ in the aortic root (Figure 2J), 
Figure 2. CXCR4 on smooth muscle cells is atheroprotective. 
A through H, Cxcr4fl/flApoe–/– mice were crossed with a TaglnCre-expressing mouse line, triggering constitutive Cxcr4 deletion 
in SMCs. TaglnCre+Cxcr4fl/flApoe–/– mice versus TaglnCre–Cxcr4fl/flApoe–/– controls were analyzed after 12 weeks of HFD. A and 
B, Experimental scheme. C through E, Lesion area measured after Oil Red O or HE staining in the aortic root (C; n=13–24), 
aorta (D; n=6–16), and aortic arch (E; n=5–11). Representative pictures are shown for aortic root (Left). Scale bars=500 µm. 
F, Macrophage content in aortic root lesions, quantified after Mac2 staining (n=5–16). G, Necrotic core area in aortic root 
lesions, as quantified by anucleated area measurement (n=6–16). H, SMC content in aortic root lesions was quantified after 
staining for SMA and expressed relative to the number of plaque cells (n=13–23). Representative images are shown (Left). I 
through O, Cxcr4fl/flApoe–/– mice were crossed with SmmhcCreERT2-expressing mice (termed SmmhcCre) to allow for tamoxifen-
inducible Cxcr4 deletion in SMCs. SmmhcCre+Cxcr4fl/fl Apoe–/– mice versus SmmhcCre–Cxcr4fl/flApoe–/– controls were analyzed 
after 12 weeks of HFD. I, Experimental scheme. J through O, Lesional area measured after Oil Red O or HE staining in the 
aortic root (J; n=12–15), aortic arch (K; n=10–13), and aorta (L; n=12–13). Representative pictures are shown for aortic root 
(J). Scale bars=500 µm. M through O, Quantification of SMC and macrophage content expressed relative to the number of 
plaque cells (M and N, n=12–14) and necrotic core area in aortic root lesions, as quantified by measuring the anucleated area 
(O, n=12–13). (C through O, Data represent mean±SD. *P<0.05. **P<0.01, as analyzed by Student t test with Welch correc-
tion or Mann-Whitney test, as appropriate. HE indicates hematoxylin and eosin; HFD, high-fat diet; SMA, smooth muscle actin; 
and SMC, smooth muscle cell.
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a significant increase in lesion size was observed in 
the aortic arch and in the aorta of SmmhcCre+Cxcr4fl/
fl Apoe–/– mice versus SmmhcCre–Cxcr4fl/flApoe–/– con-
trols after 12 weeks of HFD (Figure 2K and 2L). The 
lesional content of SMCs and macrophages and the 
necrotic core area (Figure  2M through 2O, online-
only Data Supplement Figure III through IIK) in aortic 
root lesions were unchanged. No differences in pe-
ripheral blood leukocyte and platelet counts, body 
weight, plasma levels of cholesterol, triglycerides, 
and CXCL12 were observed between SmmhcCre+ and 
SmmhcCre–Cxcr4fl/flApoe–/– mice after HFD (online-
only Data Supplement Figure IIL and IIM, online-only 
Data Supplement Table VII). Furthermore, bone mar-
row (BM) reconstitution studies revealed that CXCR4 
on BM-derived ECs does not affect atherosclerosis, 
whereas CXCR4 on a subset of BM-derived SMCs is 
proatherogenic (online-only Data Supplement Figure 
III, online-only Data Supplement Tables VII and VIII). 
These effects are apparently unrelated to the function 
of CXCR4 in resident vascular cells.
Endothelial CXCR4 Reduces Vascular 
Permeability Through WNT/β-Catenin
To identify the processes underlying the atheroprotective 
functions of endothelial CXCR4, we examined its role 
in vascular permeability, which is crucially regulated by 
the EC layer,19 also given that increased permeability is 
associated with enhanced atherosclerosis.20 Histamine-
induced vascular permeability was increased in C57/
Bl6 mice pretreated with the CXCR4 antagonist 
AMD3465 for 16 hours (Figure  3A through 3C), 
whereas systemic pretreatment with the CXCR4 
ligand CXCL12 for 4 hours reduced histamine-induced 
vascular permeability (Figure  3D). Under conditions 
of HFD, vascular permeability was increased in Apoe–/– 
mice with an endothelial-specific Cxcr4 deficiency (Fig-
ure 3E through 3G, phosphate-buffered saline–treated 
group). Similarly, blockade of CXCR4 with AMD in-
creased vascular permeability in Apoe–/– mice but did 
not affect vascular permeability in BmxCre+ versus 
BmxCre–Cxcr4fl/flApoe–/– mice (Figure 3F and 3G). In vi-
tro, the permeability of hAoECs, which express CXCR4 
on their surface (online-only Data Supplement Figure 
IVA), to fluorescein isothiocyanate-dextran was in-
creased by activation with the inflammatory cytokine 
tumor necrosis factor α (online-only Data Supplement 
Figure IVB). In contrast, permeability was reduced by 
treatment of hAoECs with CXCL12 for 24 hours and 
even by short stimulation with CXCL12 for 15 min-
utes (Figure  3H through 3J). These effects were pre-
vented by the CXCR4 antagonist AMD3100 (Figure 3H 
through 3J), indicating that a CXCL12/CXCR4-mediat-
ed mechanism protects the EC barrier function. Like-
wise, blockade of Akt kinase signaling downstream of 
CXCR4 using SH5 prevented the reduction in endothe-
lial permeability by CXCL12 (Figure 3K).
Because WNT signaling has been reported to 
reduce leakage of the blood-brain barrier21 and β-
catenin is present in endothelium covering human 
atherosclerotic lesions (online-only Data Supplement 
Figure IVC), we examined a potential role for WNT/β-
catenin in CXCL12-mediated protection of arterial 
endothelial barrier function using a luciferase reporter 
assay (Figure  4A). In hAoECs, CXCL12 induced a 
marked increase in WNT activity, which was inhibited 
by a CXCR4 antagonist, by small intervening RNA–
mediated CXCR4 knock-down or by endo-IWR1 
as a specific WNT inhibitor (Figure  4B, online-only 
Data Supplement Figure IVD). Treatment of hAoECs 
with CXCL12 upregulated β-catenin transcript levels 
(online-only Data Supplement Figure IVE). Likewise, 
CXCL12 increased both cytoplasmic and nuclear β-
catenin protein levels, an effect blocked by silencing 
CXCR4 or by inhibiting WNT signaling with endo-IWR1 
(Figure 4C, online-only Data Supplement Figure IVF). 
Accordingly, transcript expression of the WNT target 
genes MT1, cyclin-D1, and axin-2 was upregulated 
by CXCL12 (online-only Data Supplement Figure 
IVG). It is noteworthy that treatment with the WNT 
protein WNT3a, which triggers β-catenin stabilization 
by binding to the Frizzled receptor, or with the GSK3 
inhibitor LiCl to stimulate WNT signaling reduced 
endothelial permeability (Figure 4D). The reduction of 
endothelial permeability induced by CXCL12 treatment 
for 24 hours or 15 minutes could be reversed by endo-
IWR1 (Figure 4E, online-only Data Supplement Figure 
IVH). Together, our data indicate that CXCL12 improves 
endothelial barrier function through the WNT pathway.
Endothelial CXCR4 Sustains VE-Cadherin 
Expression and Function
The adherens junctional protein VE-cadherin is an im-
portant contributor to endothelial barrier function.19 
Because CXCL12 regulates E-cadherin expression and 
localization in migrating epithelial cells,22 we tested a 
role of VE-cadherin in the CXCL12/CXCR4-mediated 
control of endothelial permeability. In hAoECs, CXCL12 
increased transcript and protein expression of VE-cad-
herin (Figure  4F, online-only Data Supplement Figure 
IVI). This was paralleled by reduced protein levels of 
VE-cadherin in carotid artery lysates of BmxCre+Cxcr4fl/
flApoe–/– mice in comparison with controls (Figure 4G). 
Of note, inhibiting WNT signaling with endo-IWR1 
prevented the upregulation of VE-cadherin mRNA and 
protein levels by CXCL12 (Figure 4F, online-only Data 
Supplement Figure IVI), indicating that VE-cadherin 
expression is increased by the CXCL12/WNT pathway. 
The VE-cadherin–associated phosphatases SHP2, PTP1B, 
Döring et al
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and VE-PTP are known to sustain VE-cadherin function 
and endothelial barrier integrity.23,24 Blocking SHP2 and 
PTPB1 prevented the reduction of endothelial permea-
bility induced by CXCL12 or WNT3a (Figure 4H). Impor-
tantly, an increase in histamine-triggered vascular per-
meability on CXCR4 blockade could not be observed 
in engineered VE-PTP-FRB+/VE-cadherin-FKBP C57/Bl6 
knock-in mice featuring a nondissociating, thus sta-
bilized interaction between VE-cadherin and VE-PTP, 
which is induced by the chemical compound rapalog 
and has been previously linked to a preservation of the 
endothelial barrier23 (Figure  4I through 4K). Together, 
our data show that the CXCL12/CXCR4 axis maintains 
endothelial integrity through the activity of VE-cadherin 
and VE-cadherin–regulating phosphatases.
CXCL12/CXCR4 signaling did not alter the expression 
of other tight junctional proteins or inflammatory mark-
ers in ECs (data not shown). Finally, because vascular 
tone regulators such as endothelial nitric oxide synthase 
have been shown to influence atherogenesis25 and the 
EC layer critically regulates vascular tone, we exam-
ined a possible role for endothelial CXCR4 in vascular 
reactivity. No differences were observed in the vascular 
contraction or relaxation of aortic rings from BmxCre+ 
Figure 3. Endothelial CXCR4 reduces vascular permeability through WNT signaling.  
A and B, Experimental scheme. C, Histamine-induced (10 µg IV for 10 minutes) vascular permeability to Evans blue in C57/Bl6 
mice pretreated with the CXCR4 antagonist AMD3465 (125 µg/mouse) or vehicle (PBS) for 16 hours, as indicated (n=8–13; 
Student t test with Welch correction). Representative images are shown (Left). D, Histamine-induced (10 µg histamine IV for 
10 minutes) vascular permeability to Evans blue in C57/Bl6 mice pretreated for 4 hours with CXCL12 (3 µg) or vehicle (PBS), as 
indicated (n=8–13; Student t test with Welch correction). Representative images are shown (Left). E, Experimental scheme. F 
and G, Evans blue extravasation in the aortic arch of BmxCre–Cxcr4fl/flApoe–/– and BmxCre+ Cxcr4fl/flApoe–/– mice after 12 weeks 
of HFD and treated with the CXCR4 antagonist AMD3465 (125 µg/mouse) or vehicle (PBS) for 12 hours, as indicated (n=9–21; 
2-way ANOVA with Bonferroni post test). Representative images are shown (Left). H, Experimental scheme. I and J, Permeabil-
ity of hAoECs to FITC-Dextran after stimulation with CXCL12 (100 ng/mL) for 24 hours (I) or 15 minutes (J). Where indicated, 
cells were pretreated with the CXCR4 antagonist AMD3100 (I) or AMD3465 (J) at 1 µg/mL for 1 hour before CXCL12 stimula-
tion. Data in I represent n=17 to 20 wells from 7 independent experiments (Kruskal-Wallis test with the Dunn post test). Data 
in J represent n=11 to 19 wells from 6 independent experiments (1-way ANOVA with the Tukey multiple comparisons test). 
K, Permeability of hAoECs to FITC-Dextran after stimulation for 15 minutes with CXCL12 (100 ng/mL) and pretreated with 
the Akt inhibitor SH-5 (20 nmol/L) for 30 minutes, as indicated (n=6–8 wells from 4 independent experiments; Kruskal-Wallis 
test with the Dunn post test). C through K, Graphs represent mean±SD, *P<0.05. **P<0.01. ***P<0.001. ANOVA indicates 
analysis of variance; EVB, Evans blue; FITC, fluorescein isothiocyanate; hAoEC, human aortic endothelial cell; HFD, high-fat 
diet; PBS, phosphate-buffered saline; and Tamox., tamoxifen. 
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Figure 4. CXCL12/CXCR4 sustains endothelial barrier function through WNT/β-catenin regulating VE-cadherin.  
A, Experimental scheme. B, WNT activity in hAoECs as determined in a Gaussia luciferase WNT reporter assay, after 
stimulation with CXCL12 (100 ng/mL) for indicated periods. Cells were pretreated by the CXCR4 antagonist AMD3100 (1 
µg/mL) or CXCR4 knock-down was performed using siRNA (CXCR4 kd). WNT activation was blocked by the WNT inhibitor 
endo-IWR1 (10 µmol/L) (n=3; 1-way ANOVA with the Sidak multiple comparisons test). C, β-Catenin protein levels in cy-
toplasmic and nuclear extracts of hAoECs after stimulation with CXCL12 (100 ng/mL) for 24 hours. Cells were pretreated 
with endo-IWR1 (10 µmol/L). Silencing of CXCR4 was performed using siRNA (CXCR4 kd). β-Catenin levels were normal-
ized to cytoplasmic (tubulin) and nuclear (lamin β1) loading controls, respectively, and presented relative to untreated 
controls, as quantified by densitometry (n=3; 1-way ANOVA with the Tukey multiple comparisons test). A representative 
Western blot (left) and densitometry quantification (right) is shown. D, Permeability of hAoECs to FITC-dextran after 
stimulation with WNT3a (200 ng/mL) or the WNT activator LiCl (30 mmol/L) for 24 hours (n=5–10 wells from 4 indepen-
dent experiments; Kruskal-Wallis test with the Dunn post test). E, Permeability of hAoECs to FITC-dextran after stimulation 
with WNT3a (200 ng/mL) or CXCL12 (100 ng/mL) for 24 hours and pretreatment with endo-IWR1 (1 µmol/L) for 1 hour, 
as indicated (n=7–9 wells from 3 independent experiments; 1-way ANOVA with the Tukey multiple comparisons test). F, 
VE-cadherin protein levels in cytoplasmic extracts of hAoECs after stimulation with CXCL12 (100 ng/mL) for 24 hours and 
treatment with endo-IWR1 (10 µmol/L), as indicated. Knock-down of CXCR4 was performed using siRNA (CXCR4 kd). 
VE-cadherin expression was normalized to tubulin and presented relative to untreated, as quantified by densitometry (n=3; 
1-way ANOVA with the Tukey multiple comparisons test). A representative Western blot and densitometry quantification is 
shown. Controls received control siRNA (B, C, and F). G, Quantification of VE-cadherin expression in carotid artery lysates 
of BmxCre+ versus BmxCre–Cxcr4fl/flApoe–/– mice (n=3; Mann-Whitney test). H, Permeability of hAoECs to FITC-dextran after 
stimulation with CXCL12 (100 ng/mL) or WNT3a (200 ng/mL) for 24 hours and blockade of SHP2 (5 µmol/L) or PTP1B (25 
µmol/L) for 1 hour, as indicated (n=8–12 wells from 4 independent experiments; Kruskal-Wallis test with the Dunn post 
test). I through K, Vascular permeability to Evans blue induced by histamine (10 µg IV, 10 minutes) in VE-PTP-FRB+/VE-cad-
herin-FKBP C57/Bl6 knock-in mice pretreated with the CXCR4 antagonist AMD3465 (125 µg) for 12 hours and Rapalog 
(250 µg) for 4 hours or vehicle, as indicated (n=8–16; 2-way ANOVA with Bonferroni post test). A through K, Data present 
mean±SD (A through J) or mean±SEM (K). *P<0.05. **P<0.01. ***P<0.001. ANOVA indicates analysis of variance; EVB, 
Evans blue; FITC, fluorescein isothiocyanate; hAoEC, human aortic endothelial cell; PBS, phosphate-buffered saline; and 
siRNA, small interfering RNA.
Döring et al
July 25, 2017 Circulation. 2017;136:388–403. DOI: 10.1161/CIRCULATIONAHA.117.027646396
Figure 5. Effect of CXCR4 deletion on cholesterol efflux, vascular tone, and SMC phenotype.  
A and B, Quantification of cholesterol efflux from lipid-laden macrophages using HDL or pooled serum from TaglnCre+ 
versus TaglnCre–Cxcr4fl/flApoe–/– mice (A, n=6) or from SmmhcCre+ versus SmmhcCre–Cxcr4fl/flApoe–/– mice (B, n=4) after 12 
weeks of HFD as acceptor. Data represent mean±SD (Mann-Whitney test for comparing Cre– versus Cre+; 2-way ANOVA 
with Bonferroni post test for comparing without versus with cAMP). C, ApoA1 protein levels in serum of TaglnCre+ versus 
TaglnCre–Cxcr4fl/flApoe–/– mice after 12 weeks of HFD, as measured by Western blot analysis. A representative blot and densi-
tometry quantification is shown (n=6; mean±SD; Mann-Whitney test). D and E, Acetylcholine-induced endothelium-dependent 
relaxation (D, n=20 rings with endothelium or n=9–10 rings without endothelium from 8–9 mice) and (Continued )
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versus BmxCre–Cxcr4fl/flApoe–/– mice after 12 weeks of 
HFD or chow diet (online-only Data Supplement Figure 
VA through VC). Altogether, these data reveal an im-
portant function for endothelial CXCR4 in maintaining 
endothelial barrier integrity via VE-cadherin expression 
and function, without directly affecting the inflamma-
tory phenotype of ECs or vascular tone.
CXCR4 on SMCs Regulates Lesional 
Cholesterol Efflux
Cholesterol efflux capacity has been independently and 
inversely associated with atherosclerotic cardiovascular 
disease in patients with familial hypercholesterolemia.26 
Analysis of cholesterol efflux revealed a reduction in 
efflux capacity from lipid-laden macrophages when 
using serum from TaglnCre+ versus TaglnCre–Cxcr4fl/
flApoe–/– mice on HFD as acceptor. Such reduced 
cholesterol efflux was observed without and with 
cAMP stimulation, which enhances cellular lipid efflux 
to the apolipoprotein acceptor ApoA-1 (Figure  5A).27 
Similar results were obtained by using serum from 
atherosclerotic SmmhcCre+ versus SmmhcCre–Cxcr4fl/
flApoe–/– mice as acceptor (Figure 5B). Accordingly, serum 
levels of ApoA-1 were significantly reduced in TaglnCre+ 
versus TaglnCre–Cxcr4fl/flApoe–/– mice (Figure  5C). Thus, 
reduced cholesterol efflux may contribute to increased 
lipid retention and associated lesion size, as evidenced in 
TaglnCre+ and SmmhcCre+Cxcr4fl/flApoe–/– mice (Figure 2).
To identify mechanisms underlying the reduced SMC 
content in atherosclerotic lesions of TaglnCre+Cxcr4fl/
flApoe–/– mice, we analyzed expression of the proliferation 
marker proliferating cell nuclear antigen in aortic ly-
sates and found lower levels in atherosclerotic aortas of 
TaglnCre+Cxcr4fl/flApoe–/– mice in comparison with con-
trols after HFD but not a chow diet (online-only Data 
Supplement Figure VD and VE). Using a scratch assay, 
we observed an increase in the migratory capacity of 
hAoSMCs after stimulation with CXCL12, which was in-
hibited by using a CXCR4 antagonist (online-only Data 
Supplement Figure VF). Surface expression of CXCR4 
on hAoSMCs could be detected by flow cytometric 
analysis (online-only Data Supplement Figure VG).
CXCR4 on SMCs Supports NO-Dependent 
Vascular Reactivity
Because SMCs are crucial in regulating vascular tone, 
we examined the effects of SMC-specific Cxcr4 defi-
ciency on blood pressure and on vascular contraction 
and relaxation in organ baths. Systolic and diastolic 
blood pressure did not differ between TaglnCre+ ver-
sus TaglnCre– Cxcr4fl/flApoe–/– mice (online-only Data 
Supplement Figure VH and VI). On treatment with ace-
tylcholine, the relaxation of aortic rings isolated from 
TaglnCre+Cxcr4fl/flApoe–/– mice after HFD for 12 weeks 
was impaired in comparison with those from Tagln-
Cre–Cxcr4fl/flApoe–/– controls (Figure  5D). Acetylcholine 
induces nitric oxide (NO) production in ECs to trigger 
SMC relaxation, explaining the unresponsiveness of 
aortic rings lacking the EC layer (Figure 5D). Reduced 
relaxation capacity of TaglnCre+Cxcr4fl/flApoe–/– aor-
tic rings was also recorded after treatment with the 
NO donor (Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)
Figure 5 Continued. DETA-NONOate–induced endothelium-independent relaxation (E, n=16–18 rings with endothelium or 
n=11–16 rings without endothelium from 8–9 mice) of aortic rings from TaglnCre+ versus TaglnCre–Cxcr4fl/flApoe–/– mice after 
12 weeks of HFD, with or without removal of the endothelium, as indicated. Data represent mean±SEM (2-way repeated-
measures ANOVA with Bonferroni post test for comparing Cre– versus Cre+). F, Ratio of L-NAME-induced contraction (300 
µmol/L L-NAME) to basal precontraction without L-NAME in aortic rings from TaglnCre+ versus TaglnCre–Cxcr4fl/flApoe–/– mice 
after 12 weeks of HFD (n=20–21 rings from 8–9 mice). Data represent mean±SEM (Mann-Whitney test). G, Relative quantifi-
cation of transgrelin (Tagln), smooth muscle-myosin heavy chain (Smmhc), vimentin and CD248 (endosialin) mRNA expression 
in thoracic aortas of TaglnCre+ versus TaglnCre–Cxcr4fl/flApoe–/– and SmmhcCre+ versus SmmhcCre–Cxcr4fl/flApoe–/– mice after 
normalization to 18S rRNA (n=3–9). Data represent mean±SD, Student t test with Welch correction or Mann-Whitney test, as 
appropriate. H, Representative images and quantification of protein expression of CD248 (endosialin), vimentin, and CD68, 
and lipid deposition (Nile red) in atherosclerotic lesions (plaque cap) in mice with SMC-specific Cxcr4 deficiency, in comparison 
with controls (n=6–10). Data represent mean±SD and were analyzed by the Student t test with Welch correction or Mann-
Whitney test, as appropriate (G and H). I, Relative quantification of Tagln, smoothelin, CD248, and vimentin mRNA expression 
in hAoSMCs, pretreated with endoIWR1 (1 µmol/L) and stimulated with WNT3a (200 ng/mL), as indicated. Data are normal-
ized to Gapdh expression (mean±SD, data combined from 3–7 experiments, each performed in triplicate; 1-way ANOVA with 
the Sidak multiple comparisons test or Kruskal-Wallis test with the Dunn multiple comparisons test, as appropriate). J, Relative 
quantification of Tagln, smoothelin, CD248, and vimentin mRNA expression in hAoSMCs stimulated with (protease-resistant) 
CXCL12 (100–300 ng/mL), TGF-β (2.5 ng/mL), or PDGF-BB (20 ng/mL) as indicated. Data are normalized to Gapdh expression 
(mean±SD, data combined from 3–5 experiments, each performed in triplicate; 1-way ANOVA with the Sidak multiple com-
parison test or Kruskal-Wallis test with the Dunn multiple comparison test, as appropriate). A through J, *P<0.05. **P<0.01. 
***P<0.001. ANOVA indicates analysis of variance; DETA-NONOate, (Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-
1-ium-1,2-diolate; hAoSMC, human aortic vascular smooth muscle cell; HDL, high-density lipoprotein; HFD, high-fat diet; L-
NAME, Nω-nitro-l-arginine methyl ester; PDGF, platelet-derived growth factor; SEM, standard error of the mean; SMA, smooth 
muscle actin; SMC, smooth muscle cell; and TGF-β, transforming growth factor β. 
Döring et al
July 25, 2017 Circulation. 2017;136:388–403. DOI: 10.1161/CIRCULATIONAHA.117.027646398
amino]diazen-1-ium-1,2-diolate triggering EC-inde-
pendent relaxation (Figure 5E). A comparable reduction 
in (Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino] 
diazen-1-ium-1,2-diolate–induced relaxation was 
observed in the absence of the EC layer (Figure  5E). 
Moreover, contraction triggered by the NO synthase 
inhibitor Nω-nitro-l-arginine methyl ester was lower in 
aortic rings from TaglnCre+Cxcr4fl/fl Apoe–/– mice versus 
controls after HFD (Figure  5F). Similar results were 
obtained in rings from mice receiving a chow diet 
(online-only Data Supplement Figure VJ and VL). Of note, 
plasma levels of NO did not differ between genotypes on 
chow or HFD (online-only Data Supplement Figure VM 
and VN). This indicates that the impairment in vascular 
reactivity of TaglnCre+Cxcr4fl/flApoe–/– aortic rings was 
attributable to reduced responsiveness of SMCs rather 
than to reduced NO availability. By comparison, 
tamoxifen-induced SmmhcCre-driven deletion of 
Cxcr4 resulted in a less pronounced impairment in 
(Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]
diazen-1-ium-1,2-diolate–induced vascular relaxation 
in SmmhcCre+ versus SmmhcCre–Cxcr4fl/flApoe–/– mice 
but did not affect acetylcholine-induced relaxation or 
Nω-nitro-l-arginine methyl ester–induced contraction 
(online-only Data Supplement Figure VO through VQ). 
Collectively, our data indicate that Cxcr4 deficiency in 
SMCs exerts rather moderate effects on vascular tone 
per se and that the more marked impairment observed 
in TaglnCre+Cxcr4fl/flApoe–/– mice is likely attributable 
to the constitutive Cxcr4 deficiency during vascular 
development.
CXCR4 Maintains SMCs in a Contractile 
Phenotype
Vascular SMCs display a significant plasticity and can 
dedifferentiate from a contractile phenotype to a more 
synthetic phenotype. This SMC phenotype switching has 
recently been implicated in influencing atherosclerosis.28 
We found that mice with SMC-specific Cxcr4 deficiency 
showed an increased aortic expression of vimentin, a 
synthetic marker induced by platelet-derived growth 
factor BB,29 and of CD248 (endosialin), which is involved 
in platelet-derived growth factor–mediated cellular 
effects and associated with a synthetic SMC phenotype 
(Figure  5G, online-only Data Supplement Figure VR 
and VS).30,31 Moreover, staining for vimentin, CD248, 
CD68, and lipids (Nile red) revealed a higher prevalence 
of dedifferentiated SMCs in plaque caps of these 
mice (Figure  5H). In vitro, both WNT3a and CXCL12 
increased the expression of contractile markers (Tagln, 
smoothelin, CNN1) in cultured hAoSMCs, whereas the 
expression of synthetic markers was reduced (for CD248 
after WNT3A treatment, Figure  5I, online-only Data 
Supplement Figure VT) or not altered (after CXCL12 
treatment, Figure  5J, online-only Data Supplement 
Figure VU), respectively. Combined with our finding 
that the CXCL12/CXCR4 axis drives WNT activation 
(Figure 4B), these data reveal that the CXCL12/CXCR4/
WNT axis supports a contractile phenotype in SMCs.
CXCR4 Risk Variants Are Associated With 
Impaired CXCR4 Expression
We evaluated the relevance of our findings indicating 
a protective role of CXCR4 to human atherosclerosis. 
Immunohistochemistry in carotid endarterectomy 
specimen detected CXCR4 protein expression in both ECs 
and SMCs of human atherosclerotic lesions (Figure 6A), 
and the presence of active β-catenin indicating an 
activation of the WNT pathway, as well (Figure 6B). We 
next examined the association of all common variants 
at the CXCR4 locus with coronary heart disease (CHD) 
using data on altogether 92 516 CHD cases and 167 280 
controls (including CARDIoGRAMplusC4D [Coronary 
Artery Disease Genome Wide Replication and Meta-
analysis Plus the Coronary Artery Disease Genetics]) and 
fine mapping of data from the 1000 Genomes Project 
(see online-only Data Supplement Table IX for details 
of data sets included). Thus, we identified the C-allele 
at rs2322864 (minor allele frequency 26%) to be 
significantly associated with increased CHD risk (odds 
ratio, 1.04 for every C-allele; P=4.38×10–7) (Figure 6C) 
and with reduced CXCR4 gene expression in whole-
blood on expressive quantitative trait loci analysis 
(data not shown). It is noteworthy the C/C-genotype 
at rs2322864 was found to be linked to reduced 
CXCR4 mRNA expression in atherosclerotic plaques of 
human carotid arteries (Figure 6D). Moreover, CXCR4 
expression was lower in patients with symptomatic 
versus asymptomatic carotid stenosis, as evident by 
neurological events, eg, transient ischemic attacks 
(Figure 6E), consistent with the notion that low vascular 
CXCR4 levels give rise to increased risk for carotid and 
coronary atherosclerosis.
DISCUSSION
Our data unequivocally reveal that CXCR4 is 
atheroprotective in vascular cells by sustaining 
endothelial integrity and promoting the contractile 
phenotype of SMCs. This conclusion is supported by 
the increase in atherosclerosis on arterial EC or SMC-
specific deletion of Cxcr4 in mice, and reduced CXCR4 
expression in human carriers of a common CXCR4 risk 
variant for CHD, as well. Our results corroborate and 
extend the importance of CXCR4 in atherosclerosis 
and human disease beyond previous findings using its 
systemic blockade or disruption in bone marrow, and its 
role in stem and cancer cell migration, as well.
Sustained endothelial integrity on CXCL12/CXCR4 
signaling was mediated by (1) Akt/WNT signaling, (2) 
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involved the VE-cadherin–associating phosphatases 
VE-PTP, SHP2, and PTP1B,23,32–34 and was linked with 
(3) increased VE-cadherin expression and function, as 
evidenced by reinforced interactions of VE-cadherin 
and VE-PTP to conserve endothelial barrier function.23 
As a result, interference with the CXCL12/CXCR4 axis 
enhanced Evans blue extravasation into the vascular 
wall under conditions of acute inflammation and dur-
ing atherogenesis in vivo. Moreover, endothelial Cxcr4 
deficiency was associated with an upregulation of inter-
cellular adhesion molecule-1  expression in arterial ECs 
covering atherosclerotic lesions, reflecting their activa-
tion, and promoting atherogenic leukocyte recruitment 
and increased macrophage content in the lesions. The 
Figure 6. Relevance of CXCR4 pathway expression to human atherosclerotic disease. 
A, Staining of CXCR4 in human atherosclerotic lesions. Human carotid endarterectomy specimens were stained for CXCR4 
(brown) in combination with CD31 (Left, pink) or SMA (Right, pink). Scale bar=50 µm. Arrows indicate CXCR4+ ECs (Left) 
or CXCR4+ SMCs (Right). B, Staining for active β-catenin in human atherosclerotic lesions. Human carotid endarterectomy 
specimens were stained for active β-catenin (ABC; brown) in combination with CD31 (Left, pink) or SMA (Right, pink). 
Scale bar=50 µm. Arrows indicate ABC+ ECs (Left) or ABC+ SMCs (Right). C, Forest plot for the associations of CHD risk with 
rs2322864. We examined the association of 345 common variants at the CXCR4 locus (±25 kB) with CHD by using data on 
92 516 CHD cases and 167 280 controls (see online-only Data Supplement Table IV for details of data sets included), most no-
tably interrogating the CARDIoGRAMplusC4D data. We conducted fine-mapping studies in 12 500 myocardial infarction cases 
and 12 000 controls and genotyped all 512 variants with a minor allele frequency >0.1% identified by the 1000 Genomes 
Project at the CXCR4 locus. A P value of 5×10–5 was considered as statistically significant based on Bonferroni correction for 
857 variants. Odds ratios (OR) with 95% confidence intervals (CIs) and P values are given. The C-allele at rs2322864 was 
found to be associated with increased CHD risk (OR, 1.04; P=4.38×10–7). D, Association of rs2322864 with CXCR4 expression 
in carotid endarterectomy specimen (C/T; T/T: n=121 and C/C: n=67, Mann-Whitney test with Bonferroni correction to adjust 
for multiple comparisons). E, Correlation of CXCR4 expression with clinical carotid stenosis, as evident by neurological events, 
eg, transient ischemic attacks (A, asymptomatic, n=25; S, symptomatic, n=19, unpaired t test with Welch correction); CXCR4 
expression was normalized to β-actin expression (mean±SEM). *P<0.05. CHD indicates coronary heart disease; EC, endothelial 
cell; SEM, standard error of the mean; SMA, smooth muscle actin; and SMC, smooth muscle cell.
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latter effect was not attributable to a direct effect of the 
CXCL12/CXCR4 axis on the expression of inflammatory 
mediators and adhesion molecules in ECs, because it 
could not be stimulated or modulated by CXCL12 in 
vitro. This implies that the marked leukocyte trafficking 
into early lesions of mice lacking endothelial Cxcr4 was 
rather related to disturbed endothelial integrity and in-
creased permeability, subsequently enhancing vascular 
inflammation and adhesion molecule expression on the 
endothelium.
WNT activation was previously found to decrease 
leakage of the blood-brain barrier,21 implicating β-
catenin transcriptional activity in reduced permeability 
of brain ECs.35 A link between CXCL12 and WNT has 
been suggested in peripheral nerve sheath tumors and 
pancreatic β-cells, triggering cell growth and survival, 
respectively.36,37 We found that the CXCL12/CXCR4 
axis reduces endothelial permeability through Akt/
WNT– and VE-cadherin–mediated mechanisms, which 
may refine and underlie findings that CXCL12 or its 
analogs can reduce thrombin-induced endothelial per-
meability and pulmonary vascular leakage in a model 
of lipopolysaccharide-induced acute respiratory distress 
syndrome.38,39 Notably extending previous findings,23 
stabilizing the interaction between VE-cadherin and 
VE-PTP prevented the impairment of endothelial bar-
rier function on interference with CXCR4. Surprisingly, 
atherosclerosis-prone endothelium displays increased 
β-catenin nuclear localization.40 However, enhancing 
WNT signaling by blocking the endogenous β-catenin/
WNT inhibitor GSK3 reduced atherosclerosis and in-
flammatory endothelial VCAM-1 expression,41 further 
supporting an atheroprotective role of WNT, at least in 
part, at the endothelial level. Findings that endothe-
lial KLF4 is itself a β-catenin target gene,42 drives VE-
cadherin expression43 and is atheroprotective in ECs,44 
may provide additional evidence for a downstream link 
of CXCL12-induced β-catenin and VE-cadherin expres-
sion. Given the involvement of SHP2 in Akt signaling,45 
our data unveil that the CXCL12-CXCR4 axis can sus-
tain endothelial integrity through (1) SHP2/Akt/WNT 
signaling inducing VE-cadherin expression, and (2) 
VE-cadherin–associated phosphatases, namely, VE-PTP, 
supporting VE-cadherin stability and function.
In the second line of investigation, we show that the 
CXCL12/CXCR4 axis also favors a contractile over a syn-
thetic phenotype in arterial SMCs to explain increased 
lesion formation in mice with SMC-specific Cxcr4 defi-
ciency. Phenotype switching of contractile SMCs to a 
synthetic phenotype has long been considered to con-
tribute to atherogenesis by generating a more inflam-
matory SMC phenotype.28 A recent study supported 
this notion by documenting that loss of myocardin, 
a promotor of the contractile and noninflammatory 
SMC phenotype, increased atherosclerosis.46 Here, we 
uncover a role for a chemokine ligand/receptor axis in 
influencing SMC phenotype in the context of athero-
sclerosis. In addition to upregulating markers (vimentin 
and endosialin) associated with the synthetic SMC phe-
notype,29–31 SMC Cxcr4 deficiency increasingly switched 
SMCs in atherosclerotic lesions to a macrophage-like 
phenotype featuring costaining for CD68 and Nile red. 
Such SMC-derived macrophage-like cells have only re-
cently been identified in atherosclerotic lesions, and are 
suggested to augment atherosclerosis.28,47,48 Likewise, 
endosialin has been found to promote atherosclerosis 
through phenotypic remodeling of vascular SMCs.31 In 
accord with CXCL12 driving WNT signaling, we con-
firmed that both CXCL12 and WNT3a promoted the 
contractile phenotype of SMCs in vitro,49 consistent 
with our observations on Cxcr4 deficiency in vivo. Com-
bined with a reduced macrophage cholesterol efflux 
capacity attributable to lower ApoA1 serum levels, this 
may underlie atherogenic effects of Cxcr4 deficiency in 
SMCs. It is notable that because an autocrine loop for 
CXCR4-dependent expression of CXCL12 has been es-
tablished in ECs,10 a cross talk of CXCR4-bearing SMCs 
and ECs via CXCL12 in the arterial wall may also con-
tribute to atheroprotection. Proatherogenic effects of 
CXCR4 in BM-derived SMCs contrasted a protective 
role in resident SMCs, likely because of differential ex-
pression levels or functions depending on the cellular 
context and origin.
Genome-wide association studies have validated 
highly significant associations of variants near CXCL12 
as a lead gene in the 10q11 locus with the risk for CAD 
and myocardial infarction.11,12 Based on a more recent 
analysis, we have now extended the role of CXCL12 to 
the locus of its receptor CXCR4, showing that a com-
mon variant, the C-allele at rs2322864 was associated 
with increased risk for CHD, and the C/C-genotype was 
associated with reduced CXCR4 expression in whole 
blood and carotid atherosclerotic plaques. Of note, the 
odds ratio for CHD risk appeared to be more promi-
nent in predominantly female cohorts. CXCR4 expres-
sion was also reduced in patients with symptomatic in 
comparison with asymptomatic carotid atherosclerosis, 
indicative of a more unstable plaque phenotype. Col-
lectively, our data substantiate the protective role of the 
CXCL12/CXCR4 axis in cells of the arterial wall. Because 
global inducible Cxcr4 deficiency less markedly exacer-
bates atherosclerosis (D. Saleheen et al, unpublished 
data, 2017 ), CXCR4 may also confer proatherogenic 
effects in other cell types distinct from neutrophils, ECs, 
or SMCs; however, the identity of this cell type, eg, in 
the hematopoietic or other nonvascular cell compart-
ments, remains to be elucidated. Our data linking vari-
ants in the CXCR4 gene locus with CHD risk support 
the notion that CXCR4 is a disease-modifying receptor 
in atherosclerosis, indicating that protective effects may 
prevail, but cannot explain differences or resolve the 
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directionality in BM-related versus peripheral effects of 
CXCR4 on atherogenesis.
Our data indicate that specifically enhancing the 
atheroprotective functions of CXCR4 in different 
arterial cell types (but not in hematopoietic cells) might 
open new and exciting therapeutic options. Owing to 
interference with the role of CXCR4 in progenitor cell 
mobilization and trafficking, systemic approaches, eg, 
using noncleavable CXCL12 peptides39 or small-molecule 
agonists to boost CXCR4 function, carry a substantial risk 
of side effects and suboptimal efficacy, eg, attributable 
to proatherogenic effects of CXCR4-bearing BM-derived 
cells. To avoid such obstacles, one could envision a 
regional application of selectively targeted agonists or 
modulators through peri- or intravascular routes. This 
may be accomplished using polymer- or nanoparticle-
based delivery, as exemplified for microR-126-3p, 
which specifically derepresses CXCR4 activity in ECs.10 
Likewise, the therapeutic feasibility shown for target 
site blockers50 could be extended to blocking specific 
microRNA interactions with CXCR4.
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